{"id":"nnc0365-3769-mim8","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5314670","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Mim8 works by binding to and activating the GLP-1 receptor, which increases glucose-dependent insulin secretion, decreases glucagon secretion, and slows gastric emptying.","oneSentence":"Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:08.974Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04204408","phase":"PHASE2","title":"A Research Study Investigating Mim8 in People With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-10","conditions":"Healthy Volunteers, Haemophilia A With or Without Inhibitors","enrollment":275},{"nctId":"NCT05053139","phase":"PHASE3","title":"A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-02","conditions":"Haemophilia A, Haemophilia A With Inhibitors","enrollment":281},{"nctId":"NCT05878938","phase":"PHASE3","title":"A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-26","conditions":"Haemophilia A, Haemophilia A With Inhibitors","enrollment":61},{"nctId":"NCT05306418","phase":"PHASE3","title":"A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-04-04","conditions":"Haemophilia A With or Without Inhibitors","enrollment":70},{"nctId":"NCT05681845","phase":"PHASE1","title":"A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-02","conditions":"Haemophilia A","enrollment":205},{"nctId":"NCT05127473","phase":"PHASE1","title":"A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-07-14","conditions":"Healthy Volunteers - Haemophilia A","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NNC0365-3769 (Mim8)","genericName":"NNC0365-3769 (Mim8)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}